AstraZeneca beefs up cell therapy tool kit with gene editing deal
AstraZeneca is licensing Revvity’s gene-editing technology in a non-exclusive agreement for an undisclosed amount in order to create cell therapies for the treatment of cancer and immune-mediated diseases, Revvity said Thursday.
AstraZeneca is licensing the technology underlying Revvity’s base editing system, dubbed Pin-point. It’s designed to edit genes “without unintended impact on cell viability or functionality.” Revvity says that unlike CRISPR, which creates double-stranded DNA breaks, their editing system uses a modified Cas enzyme that only “nicks” one strand of the DNA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.